[CAS NO. 1371587-51-7] Cavosonstat

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1371587-51-7]

Catalog

HY-109027

Brand

MCE

CAS

1371587-51-7

DESCRIPTION [1371587-51-7]

Overview

MDL	-
Molecular Weight	299.71
Molecular Formula	C16H10ClNO3
SMILES	ClC(C=C(C(O)=O)C=C1)=C1C2=NC(C=CC(O)=C3)=C3C=C2

For research use only. We do not sell to patients.

Summary

Cavosonstat (N91115) is an orally active S-nitrosoglutathione reductase (GSNOR) inhibitor. Cavosonstat is a CFTR stabilizer, and can be used for cystic fibrosis research ^[1] .

In Vitro

Cavosonstat (N91115), a CFTR modulator, promotes cystic fibrosis transmembrane conductance regulator (CFTR) maturation and plasma membrane stability, with a mechanism of action complementary to CFTR correctors and potentiators ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04600778	GSNOR Therapeutics, Inc.	Chronic Obstructive Pulmonary Disease (COPD)	February 3, 2021	Phase 2
NCT02227888	Nivalis Therapeutics, Inc.	Cystic Fibrosis	October 2014	Phase 1
NCT04129931	University of North Carolina, Chapel Hill\|National Heart, Lung, and Blood Institute (NHLBI)	Asthma	December 19, 2019	Phase 2
NCT02275936	Nivalis Therapeutics, Inc.	Cystic Fibrosis	February 2015	Phase 1
NCT02589236	Nivalis Therapeutics, Inc.\|Medidata Solutions	Cystic Fibrosis	November 2015	Phase 2
NCT02500667	Nivalis Therapeutics, Inc.\|Davita Clinical Research	Drug Interaction Potentiation	June 2015	Phase 1
NCT02724527	Nivalis Therapeutics, Inc.	Cystic Fibrosis	April 2016	Phase 2
NCT02013388	Nivalis Therapeutics, Inc.	Healthy	February 2014	Phase 1
NCT02934139	Nivalis Therapeutics, Inc.	Cystic Fibrosis	October 2016	Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL ( 166.83 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.3366 mL	16.6828 mL	33.3656 mL
5 mM	0.6673 mL	3.3366 mL	6.6731 mL
10 mM	0.3337 mL	1.6683 mL	3.3366 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (8.34 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (8.34 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Scott H Donaldson, et al. Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR. J Cyst Fibros. 2017 May;16(3):371-379.